MedTrace Logo

Multi-centre Clinical Trial on Hormone Replacement Treatment in China

NCT01698164 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2012-10-02

No results posted yet for this study

Summary

This study is to evaluate the benefit/risk of hormone replacement treatment among early menopausal women in China. This is a multi-centre, random, prospective study.

Conditions

Interventions

DRUG

estradiol plus MPA

Participants are given estradiol and synthetic progestin.

DRUG

Ximingting Tablet

Participants are given phytoestrogen.

DRUG

estradiol plus progesterone

Participants are given estradiol and natural progesterone.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Aijun Sun, PH.D M.D · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01698164 on ClinicalTrials.gov